Results of Studies of Eslicarbazepine Acetate for the Treatment of Epilepsy to Be Presented at American Epilepsy Society Annual Meeting

Sepracor Inc. (Nasdaq: SEPR) today announced that clinical study data for eslicarbazepine acetate in the treatment of epilepsy will be presented at the 62^nd annual meeting of the American Epilepsy Society in Seattle on December 8, 2008. The posters will be presented in the Washington State Convention Center during the morning poster sessions.

The following posters will be presented:

• Effect of Eslicarbazepine Acetate on the Metformin Pharmacokinetics in Healthy Subjects
• An Evaluation of the Efficacy and Safety of Eslicarbazepine Acetate as Add-On Treatment in Patients With Partial-Onset Seizures: Pooled Analysis of Three Double-Blind Phase III Clinical Studies
• Population Pharmacokinetics of AEDs After Co-Administration With Eslicarbazepine Acetate in Adult Patients With Refractory Partial Epilepsy
• Population Pharmacokinetics of Eslicarbazepine Acetate in Adult Patients With Refractory Partial Seizures
• Dose-Response Population Analysis of Eslicarbazepine Acetate in Adult Patients With Refractory Partial Epilepsy
• An Evaluation of the Efficacy and Safety of Eslicarbazepine Acetate as Add-On Treatment in Adults With Refractory Partial-Onset Seizures: BIA-2093-301 Study

• An Evaluation of the Efficacy and Safety of Eslicarbazepine Acetate as Add-On Treatment in Adults With Refractory Partial-Onset Seizures: BIA-2093-302 Study
• An Evaluation of the Efficacy and Safety of Eslicarbazepine Acetate as Add-On Treatment in Adults With Refractory Partial-Onset Seizures: BIA-2093-303 Study
• Long-Term Treatment of Partial Epilepsy With Eslicarbazepine Acetate: Results of a One-Year Open-Label Extension to Study BIA-2093-301
• Long-Term Treatment of Partial Epilepsy With Eslicarbazepine Acetate: Results of a One-Year Open-Label Extension of Study BIA-2093-302
• Long-Term Treatment of Partial Epilepsy With Eslicarbazepine Acetate: Results of a One-Year Open-Label Extension of Study BIA-2093-303
• An Evaluation of Quality-of-Life and Depressive Symptoms During Long-Term Treatment With Eslicarbazepine Acetate: BIA-2093-301 Study
• An Evaluation of Quality-of-Life and Depressive Symptoms During Long-Term Treatment With Eslicarbazepine Acetate: BIA-2093-302 Study
• An Evaluation of Quality-of-Life and Depressive Symptoms During Long-Term Treatment With Eslicarbazepine Acetate: BIA-2093-303 Study

About Eslicarbazepine Acetate

Eslicarbazepine acetate is a novel voltage-gated sodium channel blocker that has been studied to reduce the frequency of partial-onset seizures when used in combination with other anti-epileptic drugs. This treatment has the potential to be a new therapeutic option for patients who continue to suffer partial seizures despite receiving treatment with other anti-epileptic agents. A Marketing Authorization Application for eslicarbazepine acetate was submitted to the European Medicines Agency (EMEA) in March 2008 by its innovator, Bial - Portela & C^a, S.A., a privately held Portuguese pharmaceutical company. Eslicarbazepine acetate, which is planned to be marketed in the European Union under the name ZEBINIX^™, is under EMEA review for the treatment of partial-onset seizures with or without secondary generalization, in combination with other anti-epileptic drugs. Sepracor acquired the rights to commercialize eslicarbazepine acetate for the U.S. and Canadian markets and is currently preparing a New Drug Application for submission to the U.S. Food and Drug Administration in early 2009.

About Sepracor

Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products that are directed toward serving large and growing markets and unmet medical needs. Sepracor's drug development program has yielded a portfolio of pharmaceutical products and candidates with a focus on respiratory and central nervous system disorders. Currently marketed products include LUNESTA^® brand eszopiclone, XOPENEX^® brand levalbuterol HCl Inhalation Solution, XOPENEX HFA^® brand levalbuterol tartrate Inhalation Aerosol, BROVANA^® brand arformoterol tartrate Inhalation Solution, OMNARIS^™ brand ciclesonide Nasal Spray and ALVESCO^® brand ciclesonide HFA Inhalation Aerosol. Sepracor's corporate headquarters are located in Marlborough, Massachusetts.

Zebinix is a trademark of Bial - Portela & C^a, S.A. Lunesta, Xopenex, Xopenex HFA and Brovana are registered trademarks of Sepracor Inc. Omnaris is a trademark and Alvesco is a registered trademark of Nycomed GmbH.

For a copy of this release or any recent release,

visit Sepracor’s web site at www.sepracor.com.